Eltrombopag is a thrombopoietin (TPO) receptor agonist that binds and activates human TPO receptor and initiates signal transduction pathways inducing marrow progenitor cells proliferation and differentiation thus increasing platelet production.
Eltrombopag is a thrombopoietin (TPO) receptor agonist that binds and activates human TPO receptor and initiates signal transduction pathways inducing marrow progenitor cells proliferation and differentiation thus increasing platelet production.
Eltrombopag is used in the following conditions:
Eltrombopag should not be used by people with the following conditions:
Eltrombopag can give rise to the following side effects:
Significant: Thromboembolic events (e.g. portal vein thrombosis), cataract formation, retinal haemorrhages, abnormal LFT, increased ALT, AST, bilirubin, risk of reticulin fibre bone marrow deposition, risk of bone marrow fibrosis w/ cytopenia; haematopoietic malignancies progression (e.g. myelodysplastic syndrome), cytogenic abnormalities, QT prolongation.
Nervous: Headache, insomnia, fatigue, paraesthesia, depression, anxiety, sleep disorder, confusional state, agitation, irritability, dizziness, attention disturbance, lethargy, memory impairment, vertigo, flu-like symptoms, asthenia, malaise, syncope.
CV: Peripheral oedema.
GI: Dyspepsia, nausea, vomiting, diarrhoea, constipation, mouth ulceration, toothache, oral herpes, gastroenteritis, decreased/increased appetite, dysgeusia, ascites, abdominal pain, dry mouth, abdominal distention or discomfort, GERD, haemorrhoids, gastritis, oesophageal varices, gingival bleeding, oral pain, dysphagia, discoloured faeces, swollen tongue, GI motility disorder, flatulence.
Resp: Nasopharyngitis, upper resp tract infection, rhinitis, cough, oropharyngeal pain, rhinorrhea, bronchitis, pharyngitis, dyspnoea, chest pain, chest discomfort, epistaxis.
Hepatic: Malignant hepatic neoplasm, hepatic encephalopathy, jaundice.
Genitourinary: UTI, chromaturia.
Endocrine: Menorrhagia, abnormal wt loss, hyper/hypoglycaemia, increased creatinine phosphokinase (CPK).
Haematologic: Anaemia, hemolytic anaemia, lymphopenia; decreased WBC, Hb, neutropenia, splenic infarction, Fe overload.
Musculoskeletal: Myalgia, arthralgia, muscle spasms, back pain, pain in extremity, musculoskeletal pain, bone pain.
Ophthalmologic: Dry eye, retinal exudates, ocular icterus, eye pruritus, octural icterus, blurring of vision, visual impairment, vitreous floaters.
Dermatologic: Rash, pruritus, alopecia, ecchymosis, petechiae, urticaria, skin lesion.
Others: Pyrexia, chills, pain.
Potentially Fatal: Severe hepatotoxicity.
Precautions
Take extra caution in patients with the following conditions:
This drug is not intended to normalise platelet count.
Interactions
Eltrombopag can interact with the following medicines:
Symptoms of overdose are:
Available Brand:
UsesWarningsSide EffectsPrecautionsOverdose & BrandsUses Ultravist is used in the following conditions: Radiographic Imaging: Iopromide injection is utilized to enhance the [...]
UsesWarningsSide EffectsPrecautionsOverdose & BrandsUses Ultramox is used in the following conditions: Respiratory Infections: Amoxicillin is often used to treat respiratory [...]
UsesWarningsSide EffectsPrecautionsOverdose & BrandsUses Ultraliv is used in the following conditions: Carnitine Orotate: Carnitine orotate is a combination of L-carnitine [...]
